Low-Dose r-ATG vs Basiliximab in Low-Risk Living-Donor Kidney Transplantation: Outcomes in Acute Rejection, Graft Function, and Infections

21 October 2025 : Original article

Nam Ho

^{ABDEF 1}, Thu Thi Nguyen^{BCDF 1}, Nam Van Do^{BCD 1}, Chi Tam Nguyen

^{BEF 1}, Su Xuan Hoang^{DEF 2}, Khanh Vo Ngoc Hoang^{BEF 3}, Trung Dinh Ngo^{ABDEF 1*}

DOI: 10.12659/AOT.949942

Ann Transplant 2025; 30:e949942

Authors information Article notes Copyright and License information

Introduction Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 2 Graft function and patient survival outcomes in low-dose r-ATG and basiliximab groups.

	Total (n=150)	Low-dose r-ATG (n=37)	BSX (n=113)	P
DFG (%)	0	0	0	0
Graft failure (%)	3 (2%)	1 (2.7%)	2 (1.77%)	1
Patient death (%)	0	0	0	0
Total BPAR (%)	19 (12.67%)	4 (10.81%)	15 (13.27%)	1
r-ATG – rabbit anti-thymocyte globulin; BSX – basiliximab; DGF – delayed graft function; BPAR – biopsy-proven acute rejection.

Back to the Article